Anavex Life Sciences Corp., of New York, said new scientific findings indicating that the selective serotonin reuptake inhibitor fluvoxamine, a drug marketed for depression, obsessive-compulsive disorder and panic disorder, prevents neuronal cell death resulting from endoplasmic reticulum stress through induction of sigma-1 receptor.